Investors

IMB is a privately held, late stage biotechnology company.  IMB's focus is to commercialize novel products to be used in the treatment of benign and malignant vascularized tumors and vascular formations.  The company's core technology has been developed for the treatment of vascularized cancer tumors and uterine fibroids.  

IMB's unique approach in the treatment of uterine fibroids is site specific, and more importantly, biodegradable, giving doctors and patients, especially those of child bearing age, a safe alternative that allows restoration of the blood supply to the uterus, post treatment.

IMB believes that giving women and their physicians a safe, easy and effective alternative to hysterectomy will encourage more women to seek treatment and find relief from their symptoms. 

For more information on investor participation, please contact us at:

780-945-6609.